A Cross-sectional Study Looking at the Effect of Radiotherapy on Carotid Intima-medial Thickness in Head and Neck Cancer
Some patients with head and neck cancer or benign tumours of the head and neck receive radiotherapy to their neck as part of their treatment. The carotid arteries are often included in the radiotherapy as collateral structures. There is some evidence to show that radiotherapy to these blood vessels can result in thickening of the artery walls some years after treatment and increased risk of stroke or TIA in the future.
Current research is now aimed towards detecting radiotherapy-related changes to the carotid arteries at an earlier stage and towards using new radiotherapy techniques to avoid treating these blood vessels if possible. The question of whether or not the use of preventive medicines like aspirin and cholesterol-lowering tablets helps to reverse this process is currently unanswered.
The aim of this study is to measure the thickness (intima-medial thickness) of irradiated carotid artery walls and compare this to unirradiated arteries. There are many other causes for thickening of arteries (such as high blood pressure, high cholesterol levels and diabetes) and these may affect the ability to measure the effect of radiotherapy change to the artery wall. In order to address this, it is ideal to look at this process in patients who have only had one side of their neck treated and use the other side as a comparison. The study will also be looking for earlier signs of radiotherapy-related changes, such as stiffening of the artery wall, inflammation in the artery wall (a very early sign of radiotherapy-related change) and some markers in the blood that may indicate that this process is taking place.
The null hypotheses of this study are:
- In irradiated carotid arteries, the mean intimal-medial thickness will be the same compared to unirradiated arteries.
- Serum biomarkers will not be elevated in radiation-induced carotid atherosclerosis.
- Development of radiation-induced carotid atherosclerosis is not affected by risk factor modulation (Aspirin, HMGCoA reductase inhibitors, smoking cessation).
- There is no difference in carotid arterial wall strain in irradiated carotid arteries versus unirradiated carotid arteries.
- Microbubble ultrasound will not be able to detect Inflammation in the carotid arteries as an early marker of atherosclerosis.
Descripción general del estudio
Estado
Condiciones
Tipo de estudio
Inscripción (Actual)
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Be 18 years or older
- Histologically confirmed cancer or benign tumours of the head and neck area treated with hemi-neck radiotherapy to ≥ 50Gy
- Received radiotherapy to the neck area more than 24 months previously
- Intervening neck dissection allowed
- Be able to provide written informed consent
Exclusion Criteria:
- Patients who have active head and neck cancer
- Patients with a prior history of carotid endarterectomy or carotid angioplasty and stenting
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
|---|
|
Cross-sectional hemi-neck RT
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The difference in mean IMT between irradiated and unirradiated carotid arteries.
Periodo de tiempo: >2 years post-radiotherapy
|
Cross-sectional study - measured at one time-point at least 2 years after radiotherapy
|
>2 years post-radiotherapy
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The prevalence of carotid artery stenosis in irradiated carotid arteries compared to unirradiated carotid arteries.
Periodo de tiempo: >2 years post-radiotherapy
|
Cross-sectional - measured at one time point at least 2 years after radiotherapy
|
>2 years post-radiotherapy
|
|
Quantify the use of risk-modifying therapy (anti-hypertensives, anti-diabetic medication, HMGCoA reductase inhibitors, smoking cessation) and their effect on radiation-induced carotid atherosclerosis.
Periodo de tiempo: > 2 years post-radiotherapy
|
Cross-sectional - measured at one time point at least 2 years after radiotherapy
|
> 2 years post-radiotherapy
|
|
Correlation of serum biomarker levels to carotid IMT and strain.
Periodo de tiempo: > 2 years post-radiotherapy
|
Cross-sectional - measured at one time point at least 2 years after radiotherapy
|
> 2 years post-radiotherapy
|
|
The difference in arterial wall strain between irradiated and unirradiated carotid arteries
Periodo de tiempo: > 2 years post-radiotherapy
|
Cross-sectional - measured at least 2 years after radiotherapy
|
> 2 years post-radiotherapy
|
|
The difference in arterial wall inflammation between irradiated and unirradiated carotid arteries
Periodo de tiempo: > 2 years post-radiotherapy
|
Cross-sectional - measured at one time point at least 2 years after radiotherapy
|
> 2 years post-radiotherapy
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Christopher M Nutting, PhD, Royal Marsden NHS Foundation Trust
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CCR 3687
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .